NCT04933695: An ongoing trial by Amgen
This trial is ongoing. It must report results 5 months, 1 week from now.
Full data
| Full entry on ClinicalTrials.gov | NCT04933695 |
|---|---|
| Title | A Phase 2, Multicenter, Open-label Study of Sotorasib (AMG 510) in Subjects With Stage IV NSCLC Whose Tumors Harbor a KRAS G12C Mutation in Need of First-line Treatment (CodeBreaK 201) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 28, 2022 |
| Completion date | May 27, 2025 |
| Required reporting date | May 27, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |